Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98

PURPOSE: To evaluate the estrogen receptor coactivator amplified in breast cancer 1 (AIB1) as a prognostic marker, as well as a predictive marker for response to adjuvant tamoxifen and/or aromatase inhibitors, in early estrogen receptor-positive breast cancer. METHOD: AIB1 was analyzed with immunohi...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkner, S., Jensen, M.-B., Rasmussen, B. B., Bendahl, P.-O., Fernö, M., Rydén, L., Mouridsen, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668343/
https://www.ncbi.nlm.nih.gov/pubmed/28766132
http://dx.doi.org/10.1007/s10549-017-4416-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668343/
https://www.ncbi.nlm.nih.gov/pubmed/28766132
http://dx.doi.org/10.1007/s10549-017-4416-0

Ejemplares similares